FY2018 EPS Estimates for Nabriva Therapeutics PLC – (NBRV) Decreased by Gabelli
Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Equities research analysts at Gabelli cut their FY2018 earnings per share (EPS) estimates for Nabriva Therapeutics in a research report issued to clients and investors on Wednesday, November 14th. Gabelli analyst K. Kedra now forecasts that the biotechnology company will earn ($2.05) per share for the year, down from their prior estimate of ($1.50). Gabelli also issued estimates for Nabriva Therapeutics’ FY2019 earnings at ($1.20) EPS, FY2020 earnings at ($0.95) EPS, FY2021 earnings at ($0.65) EPS and FY2022 earnings at ($0.35) EPS.
Other research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday. Needham & Company LLC set a $18.00 price target on shares of Nabriva Therapeutics and gave the company a “buy” rating in a report on Thursday, August 9th. Bank of America set a $5.00 price target on shares of Nabriva Therapeutics and gave the company a “buy” rating in a report on Monday, August 27th. Zacks Investment Research downgraded shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 19th. Finally, SunTrust Banks cut their price target on shares of Nabriva Therapeutics to $11.00 and set a “buy” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Nabriva Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $11.57.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in Nabriva Therapeutics by 163.9% in the 1st quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 15,501 shares during the period. Bank of America Corp DE raised its holdings in Nabriva Therapeutics by 4,353.6% in the 2nd quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 54,159 shares during the period. Dimensional Fund Advisors LP raised its holdings in Nabriva Therapeutics by 173.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock worth $563,000 after acquiring an additional 70,917 shares during the period. Wedbush Securities Inc. bought a new position in Nabriva Therapeutics in the 2nd quarter worth $371,000. Finally, Prosight Management LP raised its holdings in Nabriva Therapeutics by 73.6% in the 2nd quarter. Prosight Management LP now owns 421,414 shares of the biotechnology company’s stock worth $1,467,000 after acquiring an additional 178,725 shares during the period. Hedge funds and other institutional investors own 3.20% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
See Also: What is the yield curve?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.